# Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

> **NCT00088881** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 62 (actual)

## Conditions studied

- Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Nodal Marginal Zone B-cell Lymphoma
- Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
- Splenic Marginal Zone Lymphoma
- Stage I Adult Diffuse Large Cell Lymphoma
- Testicular Lymphoma
- Waldenström Macroglobulinemia

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** prednisone
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin
- **DRUG:** vincristine
- **RADIATION:** indium In 111 ibritumomab tiuxetan
- **RADIATION:** radiation therapy
- **PROCEDURE:** positron emission tomography

## Key facts

- **NCT ID:** NCT00088881
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-12
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2017-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088881, "Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00088881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*